Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Organon & Co. (OGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 2.30 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-07-31
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 661.00K shares, a 143.01% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 1.64M shares, a 1300.00% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 1.63M shares.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 2.02M shares, a 544.09% increase from fiscal 2024.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 313.00K shares, a 99.67% decline from fiscal 2023.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 95.00M shares, a 53.88% decline from fiscal 2022.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 206.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 4 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 661.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | 2.30M shares 10-Q · filed 2026-07-31 | 3.93M shares derived: sum of 3 quarters · filed 2026-07-31 | 3.93M shares derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2026-03-31 | 1.64M shares 10-Q · filed 2026-05-04 | 3.27M shares derived: sum of 2 quarters · filed 2026-05-04 | 3.27M shares derived: sum of 3 quarters · filed 2026-05-04 | 3.54M shares derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2025-12-31 | 1.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 1.63M shares derived: sum of 2 quarters · filed 2026-02-24 | 1.90M shares derived: sum of 3 quarters · filed 2026-02-24 | 2.02M shares 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 272.00K shares derived: sum of 2 quarters · filed 2025-11-10 | 389.00K shares 10-Q · filed 2025-11-10 | -313.30M shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-06-30 | 272.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 389.00K shares 10-Q · filed 2025-08-06 | -313.30M shares derived: sum of 3 quarters · filed 2025-11-10 | -300.30M shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-03-31 | 117.00K shares 10-Q · filed 2025-05-02 | -313.57M shares derived: sum of 2 quarters · filed 2025-11-10 | -300.57M shares derived: sum of 3 quarters · filed 2025-11-10 | -203.57M shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-12-31 | -313.69M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | -300.69M shares derived: sum of 2 quarters · filed 2025-11-10 | -203.69M shares derived: sum of 3 quarters · filed 2025-11-10 | 313.00K shares 10-K/A · filed 2025-11-10 | 313.00M shares 10-K · filed 2025-02-28 | ||
| 2024-09-30 | 13.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | 110.00M shares derived: sum of 2 quarters · filed 2024-11-01 | 314.00M shares 10-Q · filed 2024-11-01 | 320.00M shares derived: sum of 4 quarters · filed 2024-11-01 | |||
| 2024-06-30 | 97.00M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 301.00M shares 10-Q · filed 2024-08-07 | 307.00M shares derived: sum of 3 quarters · filed 2024-08-07 | 314.00M shares derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2024-03-31 | 204.00M shares 10-Q · filed 2024-05-03 | 210.00M shares derived: sum of 2 quarters · filed 2024-05-03 | 217.00M shares derived: sum of 3 quarters · filed 2024-05-03 | 217.00M shares derived: sum of 4 quarters · filed 2024-05-03 | |||
| 2023-12-31 | 6.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 13.00M shares derived: sum of 2 quarters · filed 2024-02-26 | 13.00M shares derived: sum of 3 quarters · filed 2024-02-26 | 95.00M shares 10-K · filed 2024-02-26 | |||
| 2023-09-30 | 7.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 7.00M shares derived: sum of 2 quarters · filed 2023-11-03 | 89.00M shares 10-Q · filed 2023-11-03 | 135.00M shares derived: sum of 4 quarters · filed 2023-11-03 | |||
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 82.00M shares 10-Q · filed 2023-08-09 | 128.00M shares derived: sum of 3 quarters · filed 2023-08-09 | 288.00M shares derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2023-03-31 | 82.00M shares 10-Q · filed 2023-05-05 | 128.00M shares derived: sum of 2 quarters · filed 2023-05-05 | 288.00M shares derived: sum of 3 quarters · filed 2023-05-05 | 288.00M shares derived: sum of 4 quarters · filed 2023-05-05 | |||
| 2022-12-31 | 46.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 206.00M shares derived: sum of 2 quarters · filed 2023-02-27 | 206.00M shares derived: sum of 3 quarters · filed 2023-02-27 | 206.00M shares 10-K · filed 2023-02-27 | |||
| 2022-09-30 | 160.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | 160.00M shares derived: sum of 2 quarters · filed 2022-11-04 | 160.00M shares 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | 0.00 shares 10-Q · filed 2022-08-05 | |||||
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-06 | ||||||
| 2021-12-31 | 82.00K shares 10-K · filed 2022-03-21 | ||||||
| 2021-09-30 | 53.00K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |